Pharmaceuticals

Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on…

The U.S. gets the vast majority of common, generic medications from China, meaning President Donald Trump’s steep tariffs on Chinese…

We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are…